PROCEPT BioRobotics Corporation (PRCT) Q1 2026 Earnings Call April 29, 2026 4:30 PM EDT
Company Participants
Matthew Bacso – Vice President of Investor Relations
Larry Wood – President, CEO & Director
Kevin Waters – Executive VP & CFO
Conference Call Participants
Matthew O’Brien – Piper Sandler & Co., Research Division
Nathan Treybeck – Wells Fargo Securities, LLC, Research Division
Michael Kratky – Leerink Partners LLC, Research Division
Richard Newitter – Truist Securities, Inc., Research Division
Joshua Jennings – TD Cowen, Research Division
Christopher Pasquale – Nephron Research LLC
Stephanie Piazzola – BofA Securities, Research Division
Suraj Kalia – Oppenheimer & Co. Inc., Research Division
David Rescott – Robert W. Baird & Co. Incorporated, Research Division
Mason Carrico – Stephens Inc., Research Division
Max Kruszeski – William Blair & Company L.L.C., Research Division
Presentation
Operator
Good afternoon, and welcome to PROCEPT BioRobotics First Quarter 2026 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to Matt Bacso, Vice President, Investor Relations, for a few introductory comments.
Matthew Bacso
Vice President of Investor Relations
Good afternoon, and thank you for joining PROCEPT BioRobotics First Quarter 2026 Earnings Conference Call. Presenting on today’s call are Larry Wood, Chief Executive Officer; and Kevin Waters, Chief Financial Officer.
Before we begin, I’d like to remind listeners that statements made on this conference call that relate to future plans, events or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. While these forward-looking statements are based on management’s current expectations and beliefs, these statements are subject to several risks, uncertainties, assumptions and other factors that could cause results to differ materially from the expectations expressed on this conference call. These risks and uncertainties are disclosed in more detail in PROCEPT BioRobotics filings with the Securities and Exchange Commission, all of which are
